Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia

D. Rushing, A. Goldman, G. Gibbs, R. Howe, B. J. Kennedy

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

A retrospective analysis of 67 patients with chronic myelogenous leukemia treated with hydroxyurea (41 patients) and busulfan (26 patients) compared the effectiveness of treatment and resulting survival. After 4 days of treatment, the white blood count in the hydroxyurea group fell at a rate of 31% ± 10% per day compared to 10% ± 8% for the busulfan group. At 6 months, the hemoglobin was similar, but in the busulfan group, the white blood count was significantly lower (12,500 vs. 29,900) (p=

Original languageEnglish (US)
Pages (from-to)307-313
Number of pages7
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume5
Issue number3
StatePublished - 1982
Externally publishedYes

Fingerprint

Busulfan
Hydroxyurea
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Blood Group Antigens
Hemoglobins
Therapeutics
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia. / Rushing, D.; Goldman, A.; Gibbs, G.; Howe, R.; Kennedy, B. J.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 5, No. 3, 1982, p. 307-313.

Research output: Contribution to journalArticle

Rushing, D, Goldman, A, Gibbs, G, Howe, R & Kennedy, BJ 1982, 'Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 5, no. 3, pp. 307-313.
Rushing, D. ; Goldman, A. ; Gibbs, G. ; Howe, R. ; Kennedy, B. J. / Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1982 ; Vol. 5, No. 3. pp. 307-313.
@article{344850824df845679cc43cb88cd69005,
title = "Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia",
abstract = "A retrospective analysis of 67 patients with chronic myelogenous leukemia treated with hydroxyurea (41 patients) and busulfan (26 patients) compared the effectiveness of treatment and resulting survival. After 4 days of treatment, the white blood count in the hydroxyurea group fell at a rate of 31{\%} ± 10{\%} per day compared to 10{\%} ± 8{\%} for the busulfan group. At 6 months, the hemoglobin was similar, but in the busulfan group, the white blood count was significantly lower (12,500 vs. 29,900) (p=",
author = "D. Rushing and A. Goldman and G. Gibbs and R. Howe and Kennedy, {B. J.}",
year = "1982",
language = "English (US)",
volume = "5",
pages = "307--313",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia

AU - Rushing, D.

AU - Goldman, A.

AU - Gibbs, G.

AU - Howe, R.

AU - Kennedy, B. J.

PY - 1982

Y1 - 1982

N2 - A retrospective analysis of 67 patients with chronic myelogenous leukemia treated with hydroxyurea (41 patients) and busulfan (26 patients) compared the effectiveness of treatment and resulting survival. After 4 days of treatment, the white blood count in the hydroxyurea group fell at a rate of 31% ± 10% per day compared to 10% ± 8% for the busulfan group. At 6 months, the hemoglobin was similar, but in the busulfan group, the white blood count was significantly lower (12,500 vs. 29,900) (p=

AB - A retrospective analysis of 67 patients with chronic myelogenous leukemia treated with hydroxyurea (41 patients) and busulfan (26 patients) compared the effectiveness of treatment and resulting survival. After 4 days of treatment, the white blood count in the hydroxyurea group fell at a rate of 31% ± 10% per day compared to 10% ± 8% for the busulfan group. At 6 months, the hemoglobin was similar, but in the busulfan group, the white blood count was significantly lower (12,500 vs. 29,900) (p=

UR - http://www.scopus.com/inward/record.url?scp=0020324127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020324127&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 307

EP - 313

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -